drugset / Trial / NCT04811326

Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation

NCT04811326

Phase 4 Unknown 150 enrolled Shaimaa Fawzy Abdel-rady Abdel-latif
RandomizedFactorialSingle-blindTreatment

Summary

The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK serum level in patients with non-segmental vitiligo.

Timeline

Start
2021-01-13
Primary completion
2024-02-13
Completion
2024-03-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 % Topical

Indications